Atea Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Atea Pharmaceuticals's earnings have been declining at an average annual rate of -42%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 10.6% per year.
Key information
-42.0%
Earnings growth rate
7.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 10.6% |
| Return on equity | -24.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30
Revenue & Expenses BreakdownBeta
How Atea Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -136 | 50 | 0 |
| 30 Sep 23 | 0 | -131 | 51 | 0 |
| 30 Jun 23 | 0 | -106 | 50 | 0 |
| 31 Mar 23 | 0 | -109 | 49 | 0 |
| 31 Dec 22 | 0 | -116 | 49 | 0 |
| 30 Sep 22 | 192 | 36 | 50 | 0 |
| 30 Jun 22 | 225 | 16 | 50 | 0 |
| 31 Mar 22 | 285 | 48 | 50 | 0 |
| 31 Dec 21 | 351 | 121 | 46 | 0 |
| 30 Sep 21 | 208 | 25 | 47 | 0 |
| 30 Jun 21 | 175 | 35 | 39 | 0 |
| 31 Mar 21 | 115 | 24 | 29 | 0 |
| 31 Dec 20 | 49 | -11 | 22 | 0 |
| 30 Sep 20 | 0 | -36 | 9 | -7 |
| 30 Jun 20 | 0 | -22 | 6 | -4 |
| 31 Mar 20 | 0 | -16 | 5 | -1 |
| 31 Dec 19 | 0 | -14 | 4 | 0 |
Quality Earnings: AVIR is currently unprofitable.
Growing Profit Margin: AVIR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVIR is unprofitable, and losses have increased over the past 5 years at a rate of 42% per year.
Accelerating Growth: Unable to compare AVIR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVIR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-14.6%).
Return on Equity
High ROE: AVIR has a negative Return on Equity (-24.49%), as it is currently unprofitable.